Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
South Asian Journal of Cancer|August 17, 2018
Palliative care and end-of-life measure outcomes: Experience of a tertiary care institute from South IndiaPraveen Adusumilli, Lingaraj Nayak, Vidya Viswanath, et al.
Cureus|May 11, 2026
Lymphomatosis Cerebri Presenting as Steroid-Refractory Demyelinating Disease: A Diagnostic ChallengeGenesis G Koodaly, Akshay Baheti, Suyash Kulkarni, et al.
Journal of Clinical Apheresis|August 10, 2023
Navigating the neutropenic abyss with granulocyte transfusions: Retrospective single-center analysis of effectiveness and safety in IndiaPriti Desai, Anisha Navkudkar, Bhausaheb Bagal, et al.
Head and Neck Pathology|June 8, 2022
Extranodal MALT Lymphoma in the Oral Cavity: A Series of Three Cases with Review of LiteratureRamandeep Kaur, Dhanlaxmi Shetty, Bhausaheb P Bagal, et al.
The Indian Journal of Medical Research|November 15, 2018
Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centreVikas Ostwal, Arvind Sahu, Saurabh Zanwar, et al.
JCO Global Oncology|March 7, 2025
Real-World Analysis Evaluating Treatment Eligibility and Outcomes in Patients With AML Receiving Intensive Chemotherapy: Insights From an Underrepresented PopulationHasmukh Jain, Thomas Eipe, Alok Shetty, et al.
Blood Cell Therapy|December 26, 2023
Lenalidomide with or without dexamethasone for relapsed or refractory Hodgkin lymphoma post autologous stem cell transplantKomal Kumbhalwar, Sachin Punatar, Anant Gokarn, et al.
American Journal of Blood Research|November 26, 2021
Human leukocyte antigen (HLA) alleles as predictive factors for benefit from lenalidomide in acute myeloid leukemia (AML)Sachin Punatar, Anant Gokarn, Lingaraj Nayak, et al.
American Journal of Blood Research|November 26, 2021
Long term outcome of a patient with relapsed refractory early thymic precursor acute lymphoblastic leukemia treated with daratumumabSachin Punatar, Anant Gokarn, Lingaraj Nayak, et al.
Leukemia & Lymphoma|March 9, 2023
A phase II study to evaluate the efficacy of low-dose rasburicase (1.5mg) in adolescent and adult acute leukemia and high-grade lymphomas with tumor lysis syndromeSwaratika Majumdar, Neha Sharma, Manju Sengar, et al.
Pageof 7